The 12-lead ECG remains the gold standard of diagnosing AF.8 The ECG will be positive for lack of a p-wave, an oscillatory baseline wave with varying amplitudes, irregular rhythm, and the classic irregularly irregular ventricular waves. Sensitivity and specificity of AF detection with a 12-lead ECG when interpreted by general practitioners is 80% and 92%, respectively.17 Detection of AF may require additional work-up if clinical suspicion of AF is high, yet initial 12-lead ECG is nonspecific.
The 24-hour Holter monitor allows for early detection of arrhythmias in patients with a high clinical suspicion for AF but whose initial 12-lead ECG finding are inconclusive..18 A Holter monitor is a 5- to 7-lead battery-powered cardiac device hung around the neck or secured on the waist. Continuous monitoring for 24 hours is performed and recorded. Use of the Holter monitor is often covered by insurance and is recognized as an effective tool in detecting arrhythmias before complications occur. Use of the 24-hour Holter monitor in a clinical study has demonstrated a 96.3% sensitivity and 96.8% specificity for detecting AF.19 Despite its high sensitivity and specificity, the Holter monitor may still be insufficient in the detection of asymptomatic or paroxysmal AF, as they are less likely to be detected within a 24-hour period.14,18
Technological has contributed to the development of more convenient methods of outpatient continuous cardiac recording. The Zio patch, manufactured by iRhythm Technologies, Inc, is an FDA-approved, 14-day continuous monitoring system. The device is a low-profile, self-adhesive, water-resistant patch that is adheres to the left chest wall; no leads or wires are required. This simple design allows for convenient use without interfering with daily activities.
Compared with other monitoring devices, patients preferred the patch monitors: 93.7% of users found the patch comfortable to wear compared with 51.7% who wore the Holter monitor.20 The Holter monitor still outperforms the Zio patch in detecting arrhythmias within a 24-hour window, but the Zio patch has demonstrated benefits in detecting arrhythmias outside the 24- to-48-hour window.20 With a mean wear time of 10.9 days and a median wear time of 13.0 days, the Zio patch is a convenient option for detecting intermittent arrhythmias within a 14-day period.21
Cardiac Event Monitors
Cardiac event monitors are capable of monitoring heart activity from a couple of weeks to just over a month. This device is useful when patients report AF symptoms that occur more than 1 week apart from each other. Cardiac event monitors come in 2 forms: external loop memory recorder and handheld event recorder. The looping memory recorder begins recording and stores information from a few minutes before and after abnormal input from the chest leads. The handheld event recorder allows a patient to manually capture a recording when symptoms occur.22 Because of the design of the cardiac event monitors, which rely on symptomatic stimuli or manual activation of the patient, the sensitivity ranges from 31.3% to 71.0%.23 For those individuals with more intermittent symptomatic arrhythmias, however, these devices are a good option.
Implantable Loop Recorders
Implantable loop recorders (ILRs) are small devices that are implanted subcutaneously in the chest. Continuous heart monitoring can be performed with an IRL for up to 3 years. It is a powerful tool used to discover undetected paroxysmal AF.24 An IRL is indicated when short-term monitors fail to identify arrythmias and there remains a high suspicion of AF. New generations of ILRs incorporate P-wave detection algorithms, raising sensitivity and specificity for AF detection both to 97%.25 The ILR may also be used to monitor the long-term efficacy of radiofrequency ablation, cryoballoon ablation, and anticoagulation therapy.26 An advantage of the ILR is its self-sufficiency. It requires no maintenance by the patient. Individuals do not need to carry a device around with them like the Holter and event recorders, which require human maintenance. Tools similar to the ILR are helpful in achieving accurate and precise diagnosis of AF and its subtypes.
Transthoracic and Transesophageal Echocardiograms
A transthoracic echocardiogram is indicated in the initial evaluation in all patients with AF and looks at heart size, chamber size, and valvular function, and directs further work-up and treatment modalities. A transesophageal echocardiogram (TEE) more accurately determines pressures and flow of the heart chambers and wall motion abnormalities, and detects thrombus formation in the left atrium.27,28 Indications for the use of TEE are to guide treatment of direct current cardioversion for AF. Direct current cardioversion may pose a risk for a thromboembolic event if thrombus formation was present in the left atrium or left atrial appendage, and may require prior anticoagulation.29 The use of TEE is beneficial in detecting 5% to 15% of thrombus before direct current cardioversion.6 After the indicated AF work-up, TEE helps identify risks associated with AF, in addition to other possible conditions..
When making a diagnosis of AF, additional studies are indicated to identify underlying causes, rule out other pathologies, and assess baseline disease severity. In addition to the diagnostic workup, initial studies include a complete blood count, complete metabolic panel, and thyroid-stimulating hormone.Initial studies help to identify comorbid or exacerbating conditions, such as infection, anemia, and hyperthyroidism, as well as abnormalities in renal function, hepatic function, electrolytes, and glucose levels. A chest radiograph should be performed and is useful in recognizing potential pulmonary disease or comorbid heart failure.
Detecting Subtypes of Atrial Fibrillation
Establishing the AF subtype helps tailor treatment and better understand the condition. Classifications of AF is based on the duration of symptoms and concurrent cardiac conditions (Table).6,30 AF is considered symptomatic in the presence of an irregular pulse, jugular venous flutter, palpitations, fatigue, dizziness, dyspnea, tachycardia, murmurs, or neurologic deficits, in addition to positive risk factors for AF.
A number of conditions can mimic AF and need to be ruled out, including atrial flutter, premature atrial contractions (PACs), and multifocal atrial tachycardia.31 Atrial flutter should be considered alongside AF when ECG findings are consistent with the absence of P waves and atrial tachycardia.32 Atrial flutter is characterized by a regular ventricular rhythm and a “sawtooth” pattern seen in the atrial leads II, III, and augmented limb lead aVF. PACs are caused by ectopic foci that fire before the next sinus impulse. ECG findings indicative of PAC include isolated interruptions of P-wave morphology with a regular rhythm. Patients with PACs can be differentiated from those with AF, as the PAC usually disappears when the heart rate is accelerated and is generally asymptomatic. Multifocal atrial tachycardia is considered as a differential with AF, as patients present with palpitations in both arrhythmias. The ECG displays 3 or more varying P-wave morphologies with an irregular P-P interval and increased rate of 100 to 140 beats per minute in patients with multifocal atrial tachycardia, which is not characteristic of AF.33
Differentiation may be obscure, which is why close attention to clinical symptoms, proper diagnostic workup, and use of the 12-lead ECG and indicated monitors are necessary for accurate distinction.
James Zapata, PA-C, is an emergency medicine physican assistant (EMPA) fellow at Arrowhead Regional Medical Center, in Colton, CA; Drew Zimmer, PA-C, is an EMPA at JFK Memorial Hospital, Indio, CA; Benjamin Rinard, PA-C, is an EMPA intern at St. Bernardine Medical Center in San Bernardino, CA; Amir Abdou, PA-C, is a PA at Western University of Health Sciences, Pomona, CA; Arielle Paamoni, PA-C, is a cardiology PA at Sherev Heart and Vascular Clinic, La Mesa, CA; and Catherine Chang Letherer, PA-C, is an assistant professor of Physician Assistant Education, Western University of Health Science, Pomona, CA.
1. Howlett PJ, Hatch FS, Alexeenko V, Jabr RI, Leatham EW, Fry CH. Diagnosing paroxysmal atrial fibrillation: are biomarkers the solution to this elusive arrhythmia? Biomed Res Int. 2015;2016:910267.
2. Link MS, Giugliano RP, Ruff CT. Stroke and mortality risk in patients with various patterns of atrial fibrillation: results from the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48). Circ Arrhythm Electrophysiol. 2017;10(1):e004267.
3. Schnabel RB, Pecen L, Ojeda FM. Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. Heart. 2017;103(13):1024-1030.
4. Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol. 2016;13(6):321.
5 Ball J, Carrington MJ, Wood KA, Stewart S; SAFETY Investigators. Women versus men with chronic atrial fibrillation: insights from the Standard versus Atrial Fibrillation spEcific managemenT studY (SAFETY). PLoS One, 2012;8(5):e65795.
6. January CT, Wann LS, Alpert JS; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-e76.
7. Bickley LS, & Szilagyi PG. Bates’ Guide to Physical Examination and History Taking. 12th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams;2017.
8. Freedman B, Camm J, Calkins H; AF-Screen Collaborators. Screening for atrial fibrillation: a report of the AF-SCREEN international collaboration. Circulation, 2017;135(19):1851-1867.
9. Tischer TS, Schneider R, Lauschke J, et al. Prevalence of atrial fibrillation in patients with high CHADS2- and CHA2DS2VASc-scores: anticoagulate or monitor high-risk patients? Pacing Clin Electrophysiol. 2014;37(12):1651-1657.
10. Saliba W, Gronich N, Barnett-Griness O, Rennert G. Usefulness of CHADS2 and CHA2DS2-VASc scores in the prediction of new-onset atrial fibrillation: a population based study. Am J Med. 2016;129(8):843-849.
11. Chen JY, Zhang AD, Lu HY, Guo J, Wang FF, Li ZC. CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis. J Geriatr Cardiol. 2013;10(3):258-266.
12. Haberman ZC, Jahn RT, Bose R, et al. Wireless smartphone ECG enables large-scale screening in diverse populations. J Cardiovasc Electrophysiol. 2015;26(5):520-526.
13. KardiaMobile. Alivecor website. https://www.alivecor.com/kardiamobile. Accessed December 17, 2019.
14. Treskes RW, Gielen W, Wermer MJ, et al. Mobile phones in cryptogenic strOke patients Bringing sIngle Lead ECGs for Atrial Fibrillation detection (MOBILE-AF): study protocol for a randomised controlled trial. Trials. 2017;18(1):402.
15. Chan PH, Wong CK, Poh YC, et al. Diagnostic performance of a smartphone-based photoplethysmographic application for atrial fibrillation screening in a primary care setting. J Am Heart Assoc. 2016;5(7):e003428.
16. Freedman B. Screening for atrial fibrillation using a smartphone: is there an app for that? J Am Heart Assoc. 2016;5(7):e004000.
17. Mant J1, Fitzmaurice DA, Hobbs FD. Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. BMJ. 2007;335(7616):380.
18. Chiang LK, Ng L. Holter monitoring (ambulatory electrocardiography) defined cardiac arrhythmia among patients presented with palpitation in the primary care setting. J Fam Med Health Care. 2017;3(1):12-16
19. Jiang K, Huang C, Ye SM, Chen H. High accuracy in automatic detection of atrial fibrillation for Holter monitoring. J Zhejiang Univ Sci B. 2012;13(9):751-6.
20. Barrett PM, Komatireddy R, Haaser S, et al. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. Am J Med. 2014;127(1):95:e11-e17.
21. Tung CE, Su D, Turakhia MP, Lansberg MG. Diagnostic yield of extended cardiac patch monitoring in patients with stroke or TIA. Front Neurol. 2015;5:266
22. Patten M, Maas R, Karim A, Müller HW, Simonovsky R, Meinertz T. Event-recorder monitoring in the diagnosis of atrial fibrillation in symptomatic patients: Subanalysis of the SOPAT trial. J Cardiovasc Electrophysiol. 2006;17(11):1216-1220.
23. Hindricks G, Pokushalov E, Urban L, et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation results of the XPECT trial. Circ Arrhythm Electrophysiol. 2010;3(2):141-147.
24. Frontera A, Carpenter A, Ahmed N, et al. Demographic and clinical characteristics to predict paroxysmal atrial fibrillation: insights from an implantable loop recorder population. Pacing Clin Electrophysiol. 2015;38(10):1217-1222.
25. Galli A, Ambrosini F, Lombardi F. Holter monitoring and loop recorders: from research to clinical practice. Arrhythm Electrophysiol Rev. 2016;5(2):136-143.
26 Davtyan K, Shatakhtsyan V, Poghosyan H, et al. Radiofrequency versus cryoballoon ablation of atrial fibrillation: an evaluation using ECG, Holter monitoring, and implantable loop recorders to monitor absolute and clinical effectiveness. Biomed Res Int. 2018;2018:3629384
27. Suriya S, Taqi M, Adl F, Quardi S, Sodhi A, Mortazavi M. Transthoracic echocardiogram v/s transesophageal echocardiogram in identification of intracardiac thrombus in acute ischemic stroke patients (P6.239). Neurology. 2018;90(15 Supplement):P6.239.
28. Gutierrez C, Blanchard DG. Diagnosis and treatment of atrial fibrillation. Am Fam Phys. 2016;94(6):442-52.
29. Jaakkola S, Kiviniemi TO, Airaksinen KEJ. Cardioversion for atrial fibrillation – how to prevent thromboembolic complications? Ann Med. 2018;50(7):549-555.
30. Fauchier L, Philippart R, Clementy N, et al. How to define valvular atrial fibrillation? Arch Cardiovasc Dis. 2015;108(10):530-539.
31. Thakkar S, Bagarhatta R. Detection of paroxysmal atrial fibrillation or flutter in patients with acute ischemic stroke or transient ischemic attack by Holter monitoring. Indian Heart J. 2014;66(2):188-92.
32. Huang HK, Chang SL, Lin YJ, et al. Atrial fibrillation originating from superior vena cava with atrial flutter‐electrocardiogram pattern. Pacing Clin Electrophysiol. 2017;40(7):754-761.
33. Huh J. Clinical implication of multifocal atrial tachycardia in children for pediatric cardiologist. Korean Circ J. 2018;48(2):173-175.
This article originally appeared on Clinical Advisor